Study to Understand Novel Biomarkers in Researching Dementia

Recruiting now

Conditions studied: Alzheimer Disease, Mild Cognitive Impairment, Dementia

In brief

The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.

Key facts

Study ID

NCT06547099

Run by

Washington University School of Medicine

People needed

1800

Starts

2024-08-14

Expected to finish

2028-12-01

Last updated by the study team

2026-01-16

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• At least 60 years of age
• 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider
• All SEABIRD participants will be invited to participate regardless of their cognitive status

You may not qualify if…

• Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment
• Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection
• Taking a disease-modifying drug for AD at time of enrollment
• Blood transfusion in the last three months
• Unwilling or unable to participate in all study activities

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.